Home › Releases › Biotech Results Diverge as Bladder Cancer Trial Su...
Releases

Biotech Results Diverge as Bladder Cancer Trial Succeeds, FDA Rejects Filing

Biotech Results Diverge as Bladder Cancer Trial Succeeds, FDA Rejects Filing

A Phase 3 bladder cancer trial met its primary endpoint, while the FDA declined to approve a lung cancer drug application and a Phase 2 atopic dermatitis study missed its goals. The contrasting updates came as the S&P 500 and Nasdaq Composite fell on Monday, Nov. 16, 2026.

CG Oncology said its PIVOT-006 trial of investigational cretostimogene reduced recurrence risk by 68% versus the control arm in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less after complete tumor resection. The 367-patient study ran at about 90 sites in the United States and Canada. The company plans to submit a biologics license application in the second quarter of 2027 and present topline results on Dec. 2 at the Society of Urologic Oncology Annual Meeting. The hazard ratio was 0.32 (95% CI: 0.23, 0.45; p<0.0001).

Lexeo Therapeutics reported interim Phase I/II results for investigational gene therapy LX2020 in PKP2 arrhythmogenic cardiomyopathy. High-dose cohorts showed mean reductions of 80% in non-sustained ventricular tachycardia and 44% in premature ventricular contractions at the latest assessment. Ten participants had been dosed; nine had at least 12 months of follow-up by the Oct. 15, 2026, data cutoff. Lexeo said the FDA was open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint for potential accelerated approval.

Summit Therapeutics said the FDA issued a complete response letter for its application for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The agency found substantial evidence of effectiveness had not been established without a statistically significant overall-survival improvement, according to Summit. In the Phase III HARMONi trial, the combination significantly improved progression-free survival (hazard ratio 0.52), while overall survival showed a positive but not statistically significant trend. Summit shares fell 16.5%, the Associated Press reported.

Aclaris Therapeutics said its Phase 2 ADMIRATION trial of investigational bosakitug did not meet primary or secondary endpoints in moderate-to-severe atopic dermatitis. The primary measure was percent change from baseline in Eczema Area and Severity Index score at week 24. The company reported target engagement, reductions in immune-activation biomarkers and general tolerability; it also said it had started a Phase 2b trial of modzatinib for moderate-to-severe lichen planus.

The broader market was lower: the S&P 500 fell 1.92% to 7,416.59 and the Nasdaq Composite dropped 2.49% to 24,509.76, according to CNBC's closing report. Research and Markets projects the global bladder cancer drugs market will expand from USD 6.89 billion in 2026 to USD 11.84 billion by 2032, a 9.41% compound annual growth rate.

Share:TelegramXFacebook

Read Also

Comments (0)

Leave a comment

No comments yet. Be the first!